The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

Liying Ma(University of Science and Technology of China), Wenchu Lin(Chinese Academy of Sciences)
Journal of Experimental & Clinical Cancer Research
October 17, 2020
Cited by 46


Related Papers